Lilly tipped to beat Eisai, Biogen, win $13B Alzheimer's fight - FiercePharma

1. Lilly tipped to beat Eisai, Biogen, win $13B Alzheimer's fight  FiercePharma
2. FDA lays out donanemab concerns, Lilly vigorously defends safety  Fierce Biotech
3. Eli Lilly’s Alzheimer’s drug to face safety, dosing scrutiny from FDA advisers  MarketWatch
4. FDA Raises Concerns About Lilly’s Donanemab Alzheimer’s Candidate Ahead of Adcomm  BioSpace
5. FDA reviewers ask if approval of Lilly's Alzheimer's drug should be restricted  STAT